Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.51 |
| ▸ | NR1D1 | P20393 | 3/20 | 0.43 |
| ▸ | MMP8 | P22894 | 2/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.40 |
| ▸ | ACE | P12821 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32676795 | 0.95 | PTPN1 (0.46) | PTPN1NR1D1MMP8MMP3ACE | |
| SCHEMBL32676890 | 0.95 | PTPN1 (0.46) | PTPN1NR1D1MMP8MMP3ACE | |
| SCHEMBL9849305 | 0.90 | PTPN1 (0.55) | PTPN1HDAC8ALDH1A1 | |
| SCHEMBL29780698 | 0.90 | PTPN1 (0.55) | PTPN1HDAC8ALDH1A1 | |
| SCHEMBL19329075 | 0.90 | PTPN1 (0.55) | PTPN1HDAC8ALDH1A1 | |
| SCHEMBL32677213 | 0.88 | PTPN1 (0.53) | PTPN1NR1D1MMP8MMP3HDAC8 | |
| SCHEMBL32676675 | 0.88 | PTPN1 (0.53) | PTPN1NR1D1MMP8MMP3HDAC8 | |
| SCHEMBL2730308 | 0.86 | PTPN1 (0.51) | PTPN1NR1D1MMP8MMP3HDAC8 | |
| SCHEMBL18765927 | 0.86 | PTPN1 (0.51) | PTPN1NR1D1MMP8MMP3HDAC8 | |
| SCHEMBL20720214 | 0.86 | PTPN1 (0.51) | PTPN1NR1D1MMP8MMP3HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025034858-A1 | FUSED PYRIDINES FOR THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |